Moffitt Cancer Center | Strategic Alliance Partners

May 04, 2022

The safety and efficacy of the combination of the oncolytic immunotherapy CG0070 and nivolumab is under exploration as a potential therapeutic option in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy, as part of the phase 1b CORE-002 trial.

April 28, 2022

An investigative follicle-stimulating hormone receptor–mediated CAR T-cell technology is under exploration in patients with recurrent ovarian cancer.

April 26, 2022

Oncolytic immunotherapy with talimogene laherparepvec and vusolimogene oderparepvec has the potential to provide unique clinical benefits in patients with melanoma through direct intratumoral administration.

April 22, 2022

Nikhil Khushalani, MD, discusses the mechanism of action vusolimogene oderparepvec in cancer care.

March 30, 2022

David Sallman, MD, discusses the examination of magrolimab in acute myeloid leukemia.

March 28, 2022

In acute myeloid leukemia, investigators are exploring novel agents engineered to target adhesion factors, which can mobilize persistent leukemic stem cells from the bone marrow niche.

March 23, 2022

David Sallman, MD, provides perspective on the novel agent uproleselan, its efficacy in a phase 1/2 trial, and its investigation in phase 3 trials in acute myeloid leukemia.

March 21, 2022

Philippe E. Spiess, MD, MS, FACS, discusses the rationale for investigating the MTAP pathway in genitourinary cancers.

March 21, 2022

Frederick Locke, MD, discusses the phase 3 ZUMA-7 trial examining axicabtagene ciloleucel in the second-line treatment of patients with relapsed/refractory large B-cell lymphoma, safety and efficacy findings with the therapy, and the significance of the data that have been reported to date.

March 16, 2022

David Sallman, MD, discusses the role of uproleselan (GMI-1271) when utilized in acute myeloid leukemia.

February 16, 2022

Zeynep Eroglu, MD, discusses the potential of ctDNA as a noninvasive biomarker in melanoma, outlines different assays under development, and details potential opportunities to leverage ctDNA in treatment decision making.

January 10, 2022

David Sallman, MD, discusses responses achieved a first-in-human dose escalation/dose expansion phase 1/1b clinical trial of an UltraCAR-T agent, PRGN-3006, in patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome with hypomethylating agent failure.

December 13, 2021

Axicabtagene ciloleucel demonstrated favorable efficacy in elderly patients and those with other comorbidities with large B-cell lymphoma; however, adverse events were more common in some of these populations and ECOG performance status ≥2 was associated with worse outcomes and more adverse events, according to a large real-world study presented at the 2021 ASH Annual Meeting.

December 13, 2021

Dr. Shah and Dr. Wang discuss the management of cytokine release syndrome and neurotoxicity, the referral process, and the need for academic and community collaboration for CAR T-cell therapy in hematologic malignancies.

December 13, 2021

Axicabtagene ciloleucel led to a 60% improvement in event-free survival compared with standard-of-care chemotherapy as second-line treatment for patients with relapsed/refractory large B-cell lymphoma.

December 12, 2021

Frederick Locke, MD, discusses the results of the phase 3 ZUMA-7 trial in patients with large B-cell lymphoma that were presented at the 2021 ASH Annual Meeting & Exposition.

December 11, 2021

An observational single-center study suggests that mRNA-1273 SARS CoV-2 vaccination induces a strong antibody response in patients with acute myeloid leukemia and myelodysplastic syndrome, according to observational results presented during the 2021 ASH Annual Meeting.

November 11, 2021

Although BCMA-directed CAR T-cell therapy has shown early and deep responses in patients with relapsed/refractory multiple myeloma, there is much more to learn about optimal cytokine release syndrome and neurotoxicity management and treatment sequencing, particularly as off-the-shelf T-cell therapies, bispecific antibodies, and non–BCMA-directed therapies become available.

November 02, 2021

Andrew T. Kuykendall, MD, discusses the potential for momelotinib in the treatment of patients with myelofibrosis.

November 01, 2021

Dr. Shah discusses the FDA approval of brexucabtagene autoleucel in relapsed/refractory B-cell acute lymphoblastic leukemia, key findings from the pivotal ZUMA-3 trial, and next steps with CAR T-cell therapy in the field.